PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia

2021 ◽  
pp. candisc.1771.2020
Author(s):  
Jianping Li ◽  
Julia Hlavka-Zhang ◽  
Jonathan H Shrimp ◽  
Crissandra Piper ◽  
Daphne Dupere-Richer ◽  
...  
PLoS ONE ◽  
2014 ◽  
Vol 9 (8) ◽  
pp. e103435 ◽  
Author(s):  
Sheila Xinxuan Soh ◽  
Joshua Yew Suang Lim ◽  
John W. J. Huang ◽  
Nan Jiang ◽  
Allen Eng Juh Yeoh ◽  
...  

2007 ◽  
Vol 67 (9) ◽  
pp. 4482-4490 ◽  
Author(s):  
Petra S. Bachmann ◽  
Rosemary Gorman ◽  
Rachael A. Papa ◽  
Jane E. Bardell ◽  
Jette Ford ◽  
...  

2015 ◽  
Vol 13 (22) ◽  
pp. 6299-6312 ◽  
Author(s):  
Cara E. Toscan ◽  
Marwa Rahimi ◽  
Mohan Bhadbhade ◽  
Russell Pickford ◽  
Shelli R. McAlpine ◽  
...  

Glucocorticoids form a critical component of chemotherapy regimens for pediatric acute lymphoblastic leukemia and initial poor response to glucocorticoid therapy is predictive of inferior outcome.


Blood ◽  
2010 ◽  
Vol 116 (16) ◽  
pp. 3013-3022 ◽  
Author(s):  
Petra S. Bachmann ◽  
Rocco G. Piazza ◽  
Mary E. Janes ◽  
Nicholas C. Wong ◽  
Carwyn Davies ◽  
...  

Abstract Glucocorticoids play a critical role in the therapy of lymphoid malignancies, including pediatric acute lymphoblastic leukemia (ALL), although the mechanisms underlying cellular resistance remain unclear. We report glucocorticoid resistance attributable to epigenetic silencing of the BIM gene in pediatric ALL biopsies and xenografts established in immune-deficient mice from direct patient explants as well as a therapeutic approach to reverse resistance in vivo. Glucocorticoid resistance in ALL xenografts was consistently associated with failure to up-regulate BIM expression after dexamethasone exposure despite confirmation of a functional glucocorticoid receptor. Although a comprehensive assessment of BIM CpG island methylation revealed no consistent changes, glucocorticoid resistance in xenografts and patient biopsies significantly correlated with decreased histone H3 acetylation. Moreover, the histone deacetylase inhibitor vorinostat relieved BIM repression and exerted synergistic antileukemic efficacy with dexamethasone in vitro and in vivo. These findings provide a novel therapeutic strategy to reverse glucocorticoid resistance and improve outcome for high-risk pediatric ALL.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shumaila Sayyab ◽  
Anders Lundmark ◽  
Malin Larsson ◽  
Markus Ringnér ◽  
Sara Nystedt ◽  
...  

AbstractThe mechanisms driving clonal heterogeneity and evolution in relapsed pediatric acute lymphoblastic leukemia (ALL) are not fully understood. We performed whole genome sequencing of samples collected at diagnosis, relapse(s) and remission from 29 Nordic patients. Somatic point mutations and large-scale structural variants were called using individually matched remission samples as controls, and allelic expression of the mutations was assessed in ALL cells using RNA-sequencing. We observed an increased burden of somatic mutations at relapse, compared to diagnosis, and at second relapse compared to first relapse. In addition to 29 known ALL driver genes, of which nine genes carried recurrent protein-coding mutations in our sample set, we identified putative non-protein coding mutations in regulatory regions of seven additional genes that have not previously been described in ALL. Cluster analysis of hundreds of somatic mutations per sample revealed three distinct evolutionary trajectories during ALL progression from diagnosis to relapse. The evolutionary trajectories provide insight into the mutational mechanisms leading relapse in ALL and could offer biomarkers for improved risk prediction in individual patients.


Sign in / Sign up

Export Citation Format

Share Document